Christie NHS Foundation Trust

Tumor growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumors: The GREPONET-2 study (2019) Lamarca A, Ronot M, Moalla S, Crona J, Opalinska M, Lopez CL, Pezzutti D, et al. Journal article Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded (2019) Samaratunga H, Delahunt B, Egevad L, Srigley JR, Billis A, Bostwick DG, Camparo P, et al. Journal article, Review article Ozone depletion, ultraviolet radiation, climate change and prospects for a sustainable future (2019) Barnes PW, Williamson CE, Lucas RM, Robinson SA, Madronich S, Paul ND, Bornman JF, et al. Journal article, Review article Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients’ Outcome in Neuroendocrine Tumors (NET)—The GREPONET Study (2019) Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, et al. Journal article, Review article Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study (2019) Lamarca A, Ronot M, Moall S, Crona J, Opalinska M, Lopez C, Pezzutti D, et al. Conference contribution The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe (2018) Cavo M, Terpos E, Bargay J, Einsele H, Cavet J, Greil R, De Wit E Journal article, Review article Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial (2018) Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, et al. Journal article Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study (2018) Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Vidal Trueba H, et al. Conference contribution Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study (2018) Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, et al. Conference contribution Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal L (2017) Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosee P, Binder M, et al. Journal article